Trial Profile
A phase II study of ILX651 [tasidotin] administered intravenously daily for five consecutive days once every 3 weeks in patients with inoperable locally advanced or metastatic melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tasidotin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 30 Nov 2006 Status change
- 19 Sep 2005 New trial record.